Lepu Biopharma Co., Ltd. (HKG: 2157)

Market Cap	5.46B
Revenue (ttm)	220.36M
Net Income (ttm)	-78.03M
Shares Out	1.71B
EPS (ttm)	-0.05
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,911,000
Open	3.600
Previous Close	3.550
Day's Range	3.180 - 3.600
52-Week Range	2.160 - 6.500
Beta	-0.44
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 21, 2024

About Lepu Biopharma

Lepu Biopharma Co., Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for cancer targeted therapy and immunotherapy in China and internationally. The company offers PUYOUHENG (Pucotenlimab Injection), a humanized IgG4 mAb against human PD-1 for the treatment of solid tumors and melanoma. It is also developing MRG003 that is in phase III clinical study for treating nasopharyngeal cancer, and head and neck squamous cell carcinoma; and MRG002, which is in phase III trials to treat breast and u...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2018
• Employees: 429
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2157

Financial Performance

In 2023, Lepu Biopharma's revenue was 225.35 million, an increase of 1347.16% compared to the previous year's 15.57 million. Losses were -22.10 million, -96.79% less than in 2022.

Financial numbers in CNY